News and Trends 24 Nov 2022 AI works on artificial DNA for future drug development With the help of artificial intelligence (AI), researchers at Chalmers University of Technology in Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs […] November 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 BC Platforms partners on AI-driven EU cancer data project BC Platforms (BCP), a provider of healthcare data management and analytics, has been chosen as a key partner in a European Commission (EC) project. Under the EC’s Horizon Europe program, Helsinki University Hospital (HUS), has been awarded a contract to lead a €7 million ($7.2 million) consortium project termed ONCOVALUE. BCP will work with HUS […] November 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 FDA gives IND approval for Ascletis Covid drug Ascletis Pharma Inc. has revealed that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for Covid-19. The FDA has approved Ascletis to study the safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects […] November 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 New Labiotech Health Awareness Days listings page Earlier this year, we added a page to the website with all of the global events and conferences taking place. It’s been very well received, and we’ve had plenty of messages telling us of events to add. Now, we’ve added a new resource to our site. It’s a list of all of the health and […] November 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 BIA and Exopharm sign joint research agreement to develop integrated technology Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […] November 23, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […] November 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022 What recent mixed clinical results can teach about Alzheimer’s disease 2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […] November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Concern as study says new covid sub-variant is resistant to all therapeutic antibodies All approved antibody therapies for Covid-19 are ineffective against the Omicron sub-lineage BQ.1.1. That’s the worrying news following a recent study by researchers at the German Primate Center (DPZ) – Leibniz Institute for Primate Research and Friedrich-Alexander University Erlangen-Nürnberg. Omicron sub-variant BQ.1.1 is currently on the rise worldwide. As a result of an infection with […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Khondrion’s mitochondrial diseases treatment producing positive results Clinical-stage pharmaceutical company, Khondrion, discovering and developing therapies targeting primary mitochondrial diseases announced yesterday (November 22) its wholly-owned lead asset sonlicromanol for MELAS spectrum disorder has demonstrated positive treatment results. MELAS spectrum disorder is a rare progressive mitochondrial disease and sonlicromanol will move into a phase 3 registrational study supported by favorable benefit-risk profile. The […] November 23, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 UCB publishes Lennox-Gastaut syndrome study data UCB has announced the publication of long-term open-label extension (OLE) study results of FINTEPLA (fenfluramine) CIV in the journal Epilepsia. Long-term efficacy and safety findings showed that FINTEPLA, when added to a patient’s current anti-epileptic treatment regimen for seizures associated with Lennox-Gastaut syndrome (LGS), was effective in reducing the frequency of multiple seizure types and […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Funding to develop wearable patch for type 2 diabetes A project to develop a patch worn on the cheek that delivers peptide treatments for type 2 diabetes has been awarded just under €3.8 million ($3.9 million) by the EU’s Horizon Europe RESILIENCE program. The ‘BUCCAL-PEP’ project will combine skills to develop a multifunctional biomaterial patch which allows, for the first time, delivery of peptide […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Trial to start for new heart attack drug A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […] November 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email